ArticleCancers2024

Ixazomib, Lenalidomide, and Dexamethasone (IRD) Treatment with Cytogenetic Risk-Based Maintenance in Transplant-Eligible Myeloma: A Phase 2 Multicenter Study by the Nordic Myeloma Study Group.

Anu Partanen et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.